Sabu Thomas is a Cardiology physician affiliated with University of Rochester Medicine. OpenAlex indexes 59 publications with 3,085 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 Elmwood Ave
Rochester, NY 146420001
Telephone
585-275-4290Registry record last updated 6 Jul 2023.
Clinical trials
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
Sponsor: University of Rochester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BridgeBio Pharma, Inc.Program year202525 payments$23,233openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202518 payments$16,617openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202416 payments$16,031openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.2%Angiotensin receptor-neprilysin inhibitor (ARNI)27.6%Entresto100%Part D≥20 patientsBeta blocker13.4%Metoprolol Succinate100%Part D<11 patients+ 2 more classes in this area
Nervous system
24.6%Other nervous system drugs24.6%Vyndamax100%Part D<11 patientsMetabolism & gastrointestinal
14.2%SGLT2 inhibitor14.2%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A recent review on smart sensor-integrated wound dressings: Real-time monitoring and on-demand therapeutic delivery
International Journal of Biological Macromolecules
2025 - Unlocking healing codes: Nanocarriers and signalling pathways modulation for wound repair
Materials Today Communications
2025 - Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial
Circulation Cardiovascular Quality and Outcomes
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Beck, MD
University of Rochester Medicine
Benzi Kluger, MD
University of Rochester Medicine
Darren Tabechian, MD
University of Rochester Medicine
Ayesa Mian, MD
University of Rochester Medicine
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”